TY 2699a
Alternative Names: TY-2699aLatest Information Update: 29 Jun 2025
At a glance
- Originator TYK Medicine
 - Class Antineoplastics; Small molecules
 - Mechanism of Action Cyclin-dependent kinase inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 - Available For Licensing Yes
 
Highest Development Phases
- Phase I Solid tumours
 
Most Recent Events
- 25 Apr 2025 Adverse events data from a phase I trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
 - 25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
 - 17 Aug 2023 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in China (PO) (NCT05866692)